目的系统评价索利那新治疗前列腺电切术后膀胱过度活动症的疗效。方法通过检索国内外相关对照试验,按纳入排除标准筛选文献并收集相关数据和信息,采用Cochrane协作网提供的Rev Man 5.2统计软件进行Meta分析。结果疗效评价共纳入6个临床对照试验研究,采用固定效应模型和随机效应模型对数据进行分析。结果显示,索利那新治疗前列腺电切术后膀胱过度活动症可减少患者24 h、24~48 h、48~72 h内膀胱痉挛次数及持续时间(P<0.05),缩短膀胱冲洗转淡时间、排尿次数、尿急次数、平均每日夜尿次数(P<0.05),增加平均每次排尿量(P<0.05)。组间术后拔管时间差异无统计学意义(P=0.05)。总体有效性高于对照组RR合并=1.72,其95%置信区间为[1.34,2.21],差异具统计学意义(P<0.05)。结论索利那新治疗前列腺电切术后膀胱过度活动症疗效确切,具有指导临床用药意义。 Objective To evaluate the efficacy of solifenacin in the treatment of overactive bladder after prostatectomy. Methods According to the relevant control trials at home and abroad, the screening criteria were included in the screening criteria and the data and information were collected. Meta-analysis was performed using Rev Man 5.2 statistical software provided by the Cochrane Collaboration. Results A total of 6 clinical trials were included in the efficacy evaluation. The data were analyzed using the fixed-effects model and the random-effects model. The results showed that solifenacin treatment of bladder overactive bladder surgery can reduce the 24 h, 24 ~ 48 h, 48 ~ 72 h, the number and duration of bladder spasm (P <0.05), shortening the flushing of the bladder Time, frequency of urination, frequency of urinary urgency, average nocturnal nocturnal urination (P <0.05), and increase of average urination per time (P <0.05). There was no significant difference in extubation time between the two groups (P = 0.05). The overall validity was higher than that of the control group (RR = 1.72, 95% confidence interval [1.34,2.21], the difference was statistically significant (P <0.05). Conclusion Solifacine is effective in treatment of overactive bladder after prostatectomy, which has clinical significance.